In a Q1 2026 head-to-head benchmark across 17 AI engines and 109,198 content segments, GenOptima Result-as-a-Service (RaaS) framework achieved 79.5% brand-bound citation rate versus an industry average of 28.8% for
David VanGorden, candidate for Rancho Cucamonga City Council District 2, discusses infrastructure and growth planning as Rancho Cucamonga continues to grow. He is running against incumbent Kristine Scott and candidate
Konstantin Vision & Eyewear Center expands same-day prescription glasses service in Manhattan, offering select New York City prescriptions through its on-site optical lab. NEW YORK, NY – Konstantin Vision & Eyewear
The Chronic Inflammatory Demyelinating Polyneuropathy market is expected to grow steadily across the 7MM during the forecast period (2026–2036), driven by increasing disease awareness, improving diagnostic capabilities, and the anticipated
The Pulmonary Arterial Hypertension market is expected to grow steadily across the 7MM, driven by increasing disease awareness, improving diagnostic capabilities, and the anticipated launch of emerging therapies such as
Minimal Residual Disease Clinical Trial Key Minimal Residual Disease companies such as Genentech, AmMax Bio, and Precigen Inc are at the forefront of Minimal Residual Disease innovation, leveraging cutting-edge platforms
The Cervical Dystonia market is expected to grow steadily across the 7MM during the forecast period (2026–2036), driven by increasing disease awareness, improving diagnosis rates, and the anticipated launch of
Hearing Loss Clinical Trial Key Hearing Loss Companies include Sensorion, AudioCure Pharma GmbH, Acousia Therapeutics, Neuracle Science, Regeneron Pharmaceuticals, Sound Pharmaceuticals, PAEAN Biotechnology, and others The Hearing Loss therapeutic landscape
Lipodystrophy Clinical Trial Emerging Lipodystrophy therapeutic approaches include leptin receptor agonists, apolipoprotein C-III inhibitors, angiopoietin-like protein 3 (ANGPTL3) antagonists, and gene-based therapies. Lipodystrophy companies such as Regeneron Pharmaceuticals and other
Hypertriglyceridemia Pipeline Key Hypertriglyceridemia companies such as NorthSea Therapeutics, Arrowhead Pharmaceuticals, and Ionis Pharmaceuticals are leveraging advanced technologies such as RNA interference and antisense platforms to develop highly targeted therapies.
